2. Protein Tyrosine Kinase/RTK PI3K/Akt/mTOR Apoptosis
  3. Src Akt Apoptosis
  4. Chrysotoxine

Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research.

For research use only. We do not sell to patients.

Chrysotoxine Chemical Structure

Chrysotoxine Chemical Structure

CAS No. : 156951-82-5

Size Price Stock Quantity
1 mg USD 315 Get quote 2 weeks 2 - 3 weeks
5 mg   Get quote  
10 mg   Get quote  
Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Chrysotoxine Related Antibodies

Top Publications Citing Use of Products

View All Src Isoform Specific Products:

View All Isoforms

View All Akt Isoform Specific Products:

View All Isoforms

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Chrysotoxine is a dual inhibitor of Src/Akt. Chrysotoxine suppresses cancer stem cells (CSCs) phenotypes by down-regulating Src/Akt signaling. Chrysotoxine reduces cell viability and increases apoptosis level in H460 and H23 cells instead of non-tumor cell lines. Chrysotoxine shows rapid excretion and low bioavailability in rats. Chrysotoxine is used in cancer research[1][2].

In Vitro

Chrysotoxine (50 nM, 24 h) reduces cell viability and increases apoptosis level in H460 and H23 cells[1].
Chrysotoxine (5-20 nM, 72 h) suppresses the CSC populations in H460 and H23 cells[1].
Chrysotoxine (0-20 nM, overnight) decreases the stemness of H460 and H23 cells by suppressing the Src-Akt activating mechanism[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chrysotoxine Related Antibodies

Western Blot Analysis[1]

Cell Line: 460, H23 cells
Concentration: 0-20 µM
Incubation Time: Overnight
Result: Significant decreased the p-Src and p-Akt expression in a dose-dependent manner instead of Src and Akt.
Significantly reduced the down-stream stem cell transcription factor Sox2 as the decline of p-Src in H460 and H23 cells.

Cell Viability Assay[1]

Cell Line: 460, H23 cells
Concentration: 0, 1, 5, 10, 20 and 50 µM
Incubation Time: 24 h
Result: Significantly reduced cell viability and increased H460 and H23 cells cell apoptosis at 50 µM with IC50s of 127.34 and 145.47 µM, respectively.
Showed no cytotoxic effect on non-tumor cell lines at all tested concentrations.

Cell Differentiation Assay[1]

Cell Line: 460, H23 cells
Concentration: 5-20 µM
Incubation Time: 72 h
Result: Decreased approximately 30, 60, 90 and 95% of the H460 CSC spheroid size at day 7 with treated 1, 5,10 and 20 µM Chrysotoxine, respectively.
Decreased approximately 40, 60, 80 and 92% of the H23 CSC spheroid size at day 7 with treated 1, 5,10 and 20 µM Chrysotoxine, respectively.
In Vivo

Chrysotoxine (25 mg/kg for i.v; 100 mg/kg for p.o;once) rapidly excreted and has low bioavailability in Sprague-Dawley rats model[2]. Pharmacokinetic parameters of Chrysotoxine in Sprague-Dawley rats[2]

Parameters Intravenous Oral
AUC0–t (μg h/L) 1257.6 ± 570.7 172.8 ± 118.9
AUC0–∞ (μg h/L) 1270.1 ± 560.6 202.5 ± 123.8
MRT0–t (μg h/L) 0.467 ± 0.056 1.2 ± 0.46
MRT0–∞ (μg h/L) 0.59 ± 0.21 2.4 ± 1.8
t1/2Z ( h) 1.4 ± 0.76 1.7 ± 1.1
Tmax ( h) / 0.098 ± 0.040
CLZ /F (L/h/kg) 22.9 ± 11.2 668.7 ± 396.9
VZ /F (L/kg) 55.3 ± 54.1 1443.2 ± 943.0
Cmax (μg/L) 4961.2 ± 3254.8 408.8 ± 160.5
F (%) / 3.4 ± 2.4

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Molecular Weight

318.36

Formula

C18H22O5
CAS No.
SMILES

OC1=C(C=C(C=C1OC)CCC2=CC=C(C(OC)=C2)OC)OC
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Chrysotoxine Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Chrysotoxine156951-82-5SrcAktApoptosisPKBProtein kinase BH460H23Cancer stem cellsCSCsLung cancerSprague-Dawley ratsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Salutation

Applicant Name *

 

Email Address *

Phone Number *

 

Organization Name *

Department *

 

Requested quantity *

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Chrysotoxine
Cat. No.:
HY-123298
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

Request for HNMR Report

We have received your request and will respond to you as soon as possible.